• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE
Click for more information
0.00% 46.0¢

RECCE PHARMACEUTICALS LTD - News & Media

Market Cap $102.0M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight arrow Created with Sketch.

RCE receives grant from US Department of Defence

Articles & Videos

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of Defense to develop its R327G gel.

15 Jul 2024 11:28 (AEST)

Recce Pharmaceuticals (ASX:RCE) firing on all cylinders following completion of UTI trial

Keely Lynch:RCE Pharmaceuticals has announced a capital raise following the completion of its phase one and two UTI trial. To discuss this further, I’m joined by the company CEO, James Graham. Welcome James. It’s been a busy few weeks for the company. Take us throu...

03 Jul 2024 16:58 (AEST)

Recce's R327 found effective against E.coli during clinical trial

Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.

28 Jun 2024 12:25 (AEST)

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest study using its R327 anti-infective as an IV drug.

11 Jun 2024 09:38 (AEST)

Recce steps up defence ties with burn gel presentation at Military conference

Recce Pharma (ASX:RCE) has announced it's further boosting its role as an emerging defence company operating in the US military supply chain.

03 Jun 2024 13:07 (AEST)

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial has been dosed.

15 May 2024 12:20 (AEST)

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327, which aims to treat lung infections.

09 May 2024 13:59 (AEST)

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class of anti-infective drugs.

07 May 2024 10:13 (AEST)

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in Phase I/II trials following safety board approval.

26 Apr 2024 10:39 (AEST)

Recce weighs in on Q1 2024 as cash increases 100%

Recce Pharmaceuticals, developing a new body of anti-infectives for global markets, weighs in on the last three months.

22 Apr 2024 11:11 (AEST)



(20min delay)
Last
46.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $102.0M
Open High Low Value Volume
46.0¢ 46.5¢ 46.0¢ $19.60K 42.56K

Buyers (Bids)

No. Vol. Price($)
3 41004 46.0¢
 

Sellers (Offers)

Price($) Vol. No.
46.5¢ 38272 2
View Market Depth
Last trade - 15.56pm 26/07/2024 (20 minute delay) ?
Last
46.0¢ 		  Change
0.000 ( 1.08 %)
Open High Low Volume
46.0¢ 47.0¢ 46.0¢ 5566
Last updated 12.56pm 26/07/2024 ?
RCE (ASX) Chart

Top Stories

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

MinRes (ASX:MIN) shares jumped 5% nearly right out the gate on Friday following an update from the miner it’s on track to meet FY24 production guidance.The already $50+ stock jumped 5%, perhaps surprising, if a cynic wanted to bring iron ore prices into it. The steelmaking commodi...
Capital raisings wrap: Brainchip, Ovanti, Lake and VHM Tech sector companies Ovanti Ltd and Brainchip Holdings Ltd joined Lake Resources Ltd and VHM Ltd in capital raising efforts.
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity IGO (ASX:IGO) has kicked off copper drilling on-site Encounter Resources' (ASX:ENR) Yeneena play.
Tissue Repairs soars nearly 32% on TGA approval for wound healing gel Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic Goods Administration) approval for its advanced wound healing gel TR Pro+, which contains yeast-derived active ingredient Glucoprime.At 13:25 AEDT, shares in Tissue Repai...
ASX Market Open: ASX200 to rise for Friday session | July 26 The ASX200 is set to rise 0.4% according to ASX futures around 8.30am on the final day of the week.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.